跳至主要内容
临床试验/NCT05075967
NCT05075967Enrolling By Invitation不适用

Getting to Zero Among Highest HIV Incidence (HHI) Men Who Have Sex With Men (MSM) in the American South: Testing an Integrated Strategy

HIV Prevention Trials Network1 个研究点 分布在 1 个国家目标入组 2,700 人开始时间: 2025年12月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
入组人数
2,700
试验地点
1
主要终点
To evaluate whether the HPTN 096 integrated strategy increases the number of HHI MSM clients at PHASE healthcare facilities.

研究概览

简要总结

This study will evaluate a status-neutral integrated strategy to improve access to and uptake of HIV prevention and treatment services for the highest HIV incidence (HHI) men who have sex with men (MSM) in participating communities. The ultimate goal is to establish a strategy to reduce HIV incidence among HHI MSM in the southern United States (US) by increasing the number of HHI MSM accessing prevention and treatment services, increasing uptake and use of pre-exposure prophylaxis (PrEP) among those living without HIV and increasing retention in care, and thus viral suppression, among those living with HIV.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
Male
接受健康志愿者
是

入选标准

  • •Cross-Sectional HHI MSM Client Assessment Inclusion Criteria
  • •At least 18 years of age
  • •Self-reports a lifetime history of anal sex with another man (i.e., at any time in their life)
  • •Determined to be HHI within the study community per Centers for Disease Control and Prevention surveillance data
  • •Willing and able to provide consent to participate in the study
  • •Have a medical visit scheduled during the designated sampling period at a PHASE treatment or prevention healthcare facility
  • •Cross-Sectional HHI MSM Client Assessment

排除标准

  • •Individuals who have any condition that, in the opinion of the Investigator of Record (IoR) or designee, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives, will be excluded from the cross-sectional assessment.
  • •There are no co-enrollment restrictions for participation in this assessment.
  • •----------------------------------------
  • •HHI MSM Clients In-depth Interviews (IDIs) Inclusion Criteria
  • •Met inclusion criteria for the cross-sectional HHI MSM client assessment
  • •Completed the cross-sectional HHI MSM client assessment
  • •Willing and able to provide assent/consent
  • •HHI MSM Clients IDIs Exclusion Criteria
  • •Individuals who have any condition that, in the opinion of the Investigator of Record (IoR) or designee, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives, will be excluded from the qualitative interview.
  • •There are no co-enrollment restrictions for these interviews.
  • •----------------------------------------
  • •PHASE HCF Staff IDIs Inclusion Criteria
  • •Is a staff member at a participating PHASE facility
  • •Participated in at least one PHASE activity (e.g., attended a PHASE Foundation training, participated in Extension of Community Healthcare Outcomes training, member of PHASE quality improvement team)
  • •Willing and able to provide consent
  • •PHASE HCF Staff IDIs Exclusion Criteria
  • •Individuals who have any condition that, in the opinion of the Investigator of Record (IoR) or designee, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives, will be excluded from the qualitative interview.
  • •There are no co-enrollment restrictions for these interviews
  • •----------------------------------------

研究组 & 干预措施

Integrated Strategy

Experimental

HPTN 096 is a hybrid implementation-efficacy trial that uses a single arm interrupted time series (ITS) design to test whether a status-neutral integrated strategy improves access to and uptake of HIV prevention and treatment services for HHI MSM. ITS measures a change in slope for the primary outcomes pre- and post-intervention using four one-year look backs of EMR data. The integrated strategy will be delivered in up to five selected communities in the southern US.

干预措施: Health Access Coalitions (Behavioral)

Integrated Strategy

Experimental

HPTN 096 is a hybrid implementation-efficacy trial that uses a single arm interrupted time series (ITS) design to test whether a status-neutral integrated strategy improves access to and uptake of HIV prevention and treatment services for HHI MSM. ITS measures a change in slope for the primary outcomes pre- and post-intervention using four one-year look backs of EMR data. The integrated strategy will be delivered in up to five selected communities in the southern US.

干预措施: Social Media (Behavioral)

Integrated Strategy

Experimental

HPTN 096 is a hybrid implementation-efficacy trial that uses a single arm interrupted time series (ITS) design to test whether a status-neutral integrated strategy improves access to and uptake of HIV prevention and treatment services for HHI MSM. ITS measures a change in slope for the primary outcomes pre- and post-intervention using four one-year look backs of EMR data. The integrated strategy will be delivered in up to five selected communities in the southern US.

干预措施: Peer Support (Behavioral)

Integrated Strategy

Experimental

HPTN 096 is a hybrid implementation-efficacy trial that uses a single arm interrupted time series (ITS) design to test whether a status-neutral integrated strategy improves access to and uptake of HIV prevention and treatment services for HHI MSM. ITS measures a change in slope for the primary outcomes pre- and post-intervention using four one-year look backs of EMR data. The integrated strategy will be delivered in up to five selected communities in the southern US.

干预措施: Promoting Human Autonomy Support & Empathy (PHASE) (Behavioral)

结局指标

主要结局

To evaluate whether the HPTN 096 integrated strategy increases the number of HHI MSM clients at PHASE healthcare facilities.

时间窗: Month 12

Number of HHI MSM with a visit at the HCF in the previous 12 months (Source: EMR).

To evaluate whether the HPTN 096 integrated strategy increases retention in care among HHI MSM living with HIV at PHASE healthcare facilities.

时间窗: Month 12

Number of HHI MSM living with HIV with at least two HIV medical visits to the HCF at least 90 days apart within the previous 12 months (Source: EMR)

To evaluate whether the HPTN 096 integrated strategy increases PrEP prescriptions for HHI MSM not living with HIV at PHASE healthcare facilities.

时间窗: Month 12

Any PrEP prescription among all HHI MSM without HIV with a medical visit at the HCF within the previous 12 months (Source: EMR).

次要结局

  • To evaluate whether the HPTN 096 integrated strategy increases viral suppression (<200 copies/mL) in HHI MSM living with HIV at PHASE healthcare facilities.(Month 12)
  • To evaluate whether the HPTN 096 integrated strategy increases PrEP initiation, adherence and persistence for HHI MSM not living with HIV at PHASE healthcare facilities.(Months 4, 15, 27)
  • To evaluate whether the HPTN 096 integrated strategy increases PrEP initiation, adherence and persistence for HHI MSM not living with HIV at PHASE healthcare facilities.(Month 12)
  • To assess changes in the experience of autonomy support among HHI MSM at PHASE healthcare facilities.(Months 4, 15, 27)
  • To assess changes in the experience of autonomy support among HHI MSM at PHASE healthcare facilities.(Month 17 and 27)
  • To assess how autonomy support, social support, stigma, barriers to healthcare and individual agency among HHI MSM at PHASE healthcare facilities are associated with engagement in care (including PrEP prescription and viral suppression).(Months 4, 15, 27)

研究者

发起方
HIV Prevention Trials Network
申办方类型
Network
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
3 期
A Phase III Randomized Controlled Study Of Efficacy &amp; Tolerability Of Fixed Dose Combination Of Paracetamol 500 Mg + Phenylephrine Hydrochloride 5mg + Diphenhydramine 25 Mg + Caffeine 30 Mg (Nasivion Tablets) Versus Paracetamol 500 Mg And A Fixed Dose Combination Containing Paracetamol 500 Mg + Chloropheneraminemaleate 2 Mg + Phenylephrine 10 Mg (Control) In Patients With Common Cold (Coryza)
CTRI/2009/091/000879Merck Limited200
尚未招募
3 期
A study to see if scalp cooling treatment will be effective in patients receiving chemotherapy.
CTRI/2023/01/049182Cancer Research and Statistics Foundatiion
进行中(未招募)
1 期
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) AmyloidosisAL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis )MedDRA version: 20.0 Level: PT Classification code 10002022 Term: Amyloidosis System Organ Class: 10021428 - Immune system disorders
EUCTR2016-001737-27-NLJanssen-Cilag International N.V.370
进行中(未招募)
1 期
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) AmyloidosisAL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis )MedDRA version: 20.0Level: PTClassification code 10002022Term: AmyloidosisSystem Organ Class: 10021428 - Immune system disorders
EUCTR2016-001737-27-SEJanssen-Cilag International N.V.370
进行中(未招募)
1 期
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) AmyloidosisAL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis )MedDRA version: 20.0Level: PTClassification code 10002022Term: AmyloidosisSystem Organ Class: 10021428 - Immune system disorders
EUCTR2016-001737-27-GRJanssen-Cilag International N.V.370